

COVID-19 VACCINE COMMERCIALIZATION: WHAT THIS MEANS FOR HEALTHCARE PROVIDERS/SYSTEMS

How will patients be impacted by commercialization?

Commercialization is a separate process and timeline than the end of the Public Health Emergency (PHE). It is expected that patients with private insurance or public insurance (Medicaid, Illinois All Kids, and Medicare) will continue to have the cost of vaccines covered once the PHE has ended and the federal supply of vaccines has been depleted.

Children eligible for the Vaccines For Children will be able to receive a vaccine at no cost. Adults with no insurance will likely have limited access to free vaccines. Access may be impacted by vaccine supply.

How will commercialization impact providers?

There is uncertainty about the upfront cost that may be required from providers to purchase COVID-19 vaccines at this time. As far as ordering, once commercialized, it is likely that COVID-19 vaccines will be obtained in the same way other commercialized vaccines are ordered.

The hope is that upon commercialization single-dose vials and lower-minimum quantity orders will be available.

How much will COVID-19 vaccines cost providers to purchase?

This is still unknown. The American Academy of Pediatrics (AAP) is advocating for vaccines to remain free for pediatric providers. Moderna has stated they will price their vaccine products at \$130 per dose and Pfizer has estimated their products may range between \$110 to \$130 for each dose for providers to purchase. Moderna has plans to set up a COVID-19 patient assistance program so it is offered at no cost to those who are uninsured. Novavax and Johnson & Johnson have not released any information on commercial pricing.

Will/when will vaccine schedules change?

This is also unknown at this time. There are discussions taking place around simplifying the COVID-19 vaccine schedules and products. For example, using bivalent vaccines for primary and booster doses.

Illinois Chapter

INCORPORATED IN ILLINOIS

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



I-VAC
ILLINOIS VACCINATES
AGAINST COVID-19
A project led by the Illinois Chapter
of the American Academy of Pediatrics





COVID-19 VACCINE COMMERCIALIZATION: WHAT THIS MEANS FOR HEALTHCARE PROVIDERS/SYSTEMS

What is the AAP doing to advocate for pediatricians as commercialization approaches?

The AAP is advocating for:

- Longer invoice and payment schedules so that pediatricians can be reimbursed before having to purchase additional vaccines.
- Simplified and improved labeling of COVID-19 vials to minimize errors in administration.
- An easier return process for expired doses.
- Single-dose vials for all products.

Will billing codes change once commercialization occurs?

Unknown at this time.

What does the end of federally-purchased supply of COVID-19 vaccines mean?

From the beginning of COVID-19 vaccine roll-out, the U.S. government has funded the supply and reimbursement for administrative costs of vaccines. Once the current supply of the federally purchased vaccines is depleted, consumers may have to face cost-sharing of the vaccines based on their insurance coverage.

Will there be an out-of-pocket cost for a COVID-19 vaccine?

Those with federal and state insurance plans will have their vaccines covered and will not incur any costs.


Under private insurance plans, most people will continue to pay nothing out-of-pocket for COVID-19 vaccines while federally purchased vaccine supply is available.

Illinois Chapter

INCORPORATED IN ILLINOIS

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®



March 2, 2023

